/**

*/

Tatva Chintan ends FY26 with a margin rebound, and sets up FY27 for new ramps

Tatva Chintan Pharma Chem Limited closed Q4 FY26 with revenue from operations of INR 134.1 crore, up 24% year-on-year. EBITDA (excluding other income) rose to INR 28.1 crore, with margin at 21.0%. PAT for the quarter was INR 10.3 crore.

For the full year, revenue from operations reached INR 505.9 crore, up 32% year-on-year. EBITDA (excluding other income) was INR 93.2 crore and EBITDA margin improved to 18.4%. PAT came in at INR 42.1 crore.

A key feature of FY26 was the contribution from Structure Directing Agents (SDA), which management positioned as a multi-year opportunity linked to tightening emission norms. Another notable change was Electrolyte Salts and Solutions (ESS), where Q4 FY26 showed a sharp step-up in contribution relative to earlier quarters.

FY26 numbers at a glance

What drove FY26: SDA leads, while ESS shows a new trajectory

Tatva Chintan’s FY26 revenue mix was led by SDA at 41%, followed by PASC at 32% and PTC at 23%. ESS was 3% of FY26 revenue but rose to 10% of Q4 FY26 revenue, indicating a meaningful quarter-on-quarter ramp.

In the earnings call, management reported segment revenues for Q4 FY26 of INR 31.1 crore for PTC, INR 52.5 crore for SDA, INR 13.1 crore for ESS, and INR 35.8 crore for PASC. Management attributed the quarter’s profitability improvement to a better product mix and improved operating leverage.

The SDA segment continues to be anchored in zeolite-related applications including emission control. Management highlighted that demand is expected to rise as Euro 7 norms begin implementation from 2027, starting with Europe and then expanding to other geographies over time.

ESS was described as a segment scaling gradually, supported by increasing consumption in energy storage applications. Management also stated that work with a customer in a hybrid battery application is progressing, with commercial business expected to begin in Q3 of the current year.

Capacity, capex, and execution focus: Jolva and Dahej form the next growth base

On operations, the investor presentation highlighted a combined installed reactor capacity of 791 KL and 39 assembly lines as of 31 March 2026 across Ankleshwar and Dahej SEZ. The company also emphasized its R&D setup at Vadodara (DSIR recognized), and process capabilities spanning conventional synthesis, electrolysis, and continuous flow chemistry.

Management stated that the new production block at Dahej is now fully operational on a commercial scale. During Q4, management acknowledged that dispatch delays occurred because production was being shifted and stabilized in the new block, but said that the issues have been overcome and dispatches are now moving more smoothly.

A larger strategic initiative is the greenfield project at Jolva. Management said preparatory work has progressed, with ground-breaking expected during the quarter. Based on detailed engineering work, the company refined plant design to enhance scalability and operational efficiency. Management guided that commissioning would take about 18 to 20 months, with commercial production expected around January to March 2028.

Capex guidance provided on the call was INR 100 crore in FY27 and INR 175 crore in FY28, largely for Jolva.

FY27: growth guidance held, with ESS and pharma commercialization as swing factors

Management reiterated its earlier guidance for FY27: around 25% revenue growth and EBITDA margin of 20% to 22%. They also acknowledged geopolitical uncertainty, which could affect raw material prices, freight, and customer demand patterns.

On ESS, management guided an expected contribution of about 8% to 10% of revenue in FY27, implying a sharp increase versus the FY26 share. They also suggested that recent quarterly ESS revenue levels are broadly sustainable on an annualized basis, while highlighting that the hybrid battery application is expected to begin commercial business in Q3.

On pharma, management stated that validations are complete and commercialization will start in FY27. One product is expected to commercialize in Q1 and two more from Q3, with campaign-based deliveries. Management indicated an incremental revenue potential of around INR 70 to 75 crore from pharma in FY27.

The semiconductor chemicals program remains longer-cycle. Management said plant-scale trials for the first product were completed successfully and dispatch will happen in the current quarter, but they expect final commercialization around 2028-29, after multiple validation stages.

Takeaways

Tatva Chintan’s FY26 performance reflects a recovery in profitability, supported by product mix and operating leverage. SDA remains the largest contributor, and management is positioning Euro 7 related demand as a tailwind over the next few years.

FY27 will hinge on execution across multiple ramps. ESS is expected to move from a small segment to a meaningful contributor, pharma commercialization is scheduled to begin, and the Jolva greenfield project is intended to expand domestic-focused capacity and flexibility from early 2028. At the same time, management acknowledged that geopolitical volatility and raw material inflation remain key external variables that can influence near-term margins and customer behavior.